NLEM 2022: Analysts see no major impact pharma companies' growth

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

The latest revision of the National List of Essential Medicines (NLEM) that included 34 new drugs and removed 26 is unlikely to have a noticeable impact on the domestic pharmaceutical market, felt analysts and industry insiders.

The National Pharmaceutical Pricing Authority (NPPA) controls the ceiling prices of medicines included in the NLEM, based on the wholesale price index. These are called scheduled drugs. All other drugs (non-scheduled drugs) are allowed to take up to 10 per cent hikes every year.

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM